139 related articles for article (PubMed ID: 1715080)
21. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
[TBL] [Abstract][Full Text] [Related]
22. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Cooper EH; Whelan P; Purves D
Prostate; 1994 Nov; 25(5):236-42. PubMed ID: 7526352
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
24. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
25. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
Drago JR; Badalament RA; Wientjes MG; Smith JJ; Nesbitt JA; York JP; Ashton JJ; Neff JC
Urology; 1989 Oct; 34(4):187-92. PubMed ID: 2477931
[TBL] [Abstract][Full Text] [Related]
26. Neuron-specific enolase in testicular cancer--clinical experiences with serum neuron-specific enolase in patients with testicular cancer at diagnosis and during follow-up.
Tandstad T; Klepp O
Acta Oncol; 2003; 42(3):202-6. PubMed ID: 12852696
[TBL] [Abstract][Full Text] [Related]
27. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
28. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
29. Serum carcinoembryonic antigen, neuron-specific enolase as biomarkers for diagnosis of nonsmall cell lung cancer.
Dong Y; Zheng X; Yang Z; Sun M; Zhang G; An X; Pan L; Zhang S
J Cancer Res Ther; 2016 Oct; 12(Supplement):34-36. PubMed ID: 27721249
[TBL] [Abstract][Full Text] [Related]
30. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.
Csapo Z; Brand K; Walther R; Fokas K
J Urol; 1988 Nov; 140(5):1032-8. PubMed ID: 2459419
[TBL] [Abstract][Full Text] [Related]
31. Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.
Fuse H; Umeda K; Mizuno I; Katayama T
Int Urol Nephrol; 1991; 23(5):455-63. PubMed ID: 1718922
[TBL] [Abstract][Full Text] [Related]
32. The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer.
Wang P; Piao Y; Zhang X; Li W; Hao X
Cancer Biomark; 2013; 13(2):123-30. PubMed ID: 23838141
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.
Barlési F; Gimenez C; Torre JP; Doddoli C; Mancini J; Greillier L; Roux F; Kleisbauer JP
Respir Med; 2004 Apr; 98(4):357-62. PubMed ID: 15080079
[TBL] [Abstract][Full Text] [Related]
35. Elevated tumor markers in patients with pulmonary alveolar proteinosis.
Fang SC; Lu KH; Wang CY; Zhang HT; Zhang YM
Clin Chem Lab Med; 2013 Jul; 51(7):1493-8. PubMed ID: 23314555
[TBL] [Abstract][Full Text] [Related]
36. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate].
Morote Robles J; de Torres Mateos JA
Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
[TBL] [Abstract][Full Text] [Related]
38. Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer.
Jørgensen LG; Hansen HH; Cooper EH
Eur J Cancer Clin Oncol; 1989 Jan; 25(1):123-8. PubMed ID: 2537729
[TBL] [Abstract][Full Text] [Related]
39. Cross-comparison of PSA and PAP values in a wide spectrum of prostate cancer conditions.
Tarle M
Anticancer Res; 1988; 8(4):569-72. PubMed ID: 2460018
[TBL] [Abstract][Full Text] [Related]
40. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.
Oesterling JE
J Urol; 1991 May; 145(5):907-23. PubMed ID: 1707989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
